Vrunda B. Desai
No ORCID on file
· 9 papers in corpus
observational
2026
Opportunistic salpingectomy reduces ovarian cancer risk. To examine heterogeneity among physicians in their adoption of opportunistic salpingectomy in hysterectomy practice, we identified 33,401 non-pregnant patients aged 18 to 49 years in …
observational
2025
BACKGROUND: Since professional societies recommended counseling patients about opportunistic salpingectomy for ovarian cancer risk reduction, use of opportunistic salpingectomy has increased overall. However, physicians varied in their adop…
observational
2025
OBJECTIVES: To examine variation in physician adoption of opportunistic salpingectomy (OS) for patients undergoing tubal sterilization. STUDY DESIGN: Using the Premier Healthcare Database, we identified patients age 18-49 undergoing postpa…
other
2024
Historically, the evaluation of abnormal uterine bleeding (AUB) has involved a multi-visit process that uses a multitude of care settings (eg, in-office, imaging, laboratory), with the potential for lengthy delays in care due to the now-com…
other
2022
BACKGROUND: Following a 2014 safety warning (that laparoscopic power morcellation may increase tumor dissemination if patients have occult uterine cancer), hysterectomy practice shifted from laparoscopic to abdominal approach. This avoided …
observational
2021
BACKGROUND: Safety warnings about power morcellation in 2014 considerably changed hysterectomy practice, especially for laparoscopic supracervical hysterectomy that typically requires morcellation to remove the corpus uteri while preserving…
observational
2019
BACKGROUND: Occult uterine cancer at the time of benign hysterectomy poses unique challenges in patient care. There is large variability and uncertainty in estimated risk of occult uterine cancer in the literature and prior research often d…
observational
2018
INTRODUCTION: To inform proper surgical planning and policy discussion regarding uterine power morcellation, this study estimated the prevalence of occult uterine cancer in a large population-based sample of women undergoing hysterectomy fo…
observational
2017
BACKGROUND: The selective estrogen receptor modulator tamoxifen is now widely used for the treatment and prevention of breast cancer. Tamoxifen use has been associated with a variety of gynecologic problems. Despite the frequency with which…